TGFB1 and leukemia: Apart from the suggested sensitization of solid tumors, inhibitory targeting TGFβ-mediated pathways may elevate the efficacy of CAR-T cell therapy against certain forms of leukemia if this attenuates TGFβ-provoked fibrosis in bone marrow [82].